Sign in

Private company

Sio Gene Therapies Inc.

Sio Gene Therapies Inc. is a pharmaceutical preparations company.1 It is headquartered in New York, New York.1

Last updated Oct 21, 2026.

Overview

-$71.9MNet income, fiscal 20222
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Business address1501 Broadway, 12Th Floor, New York, Ny 100363
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-119.1%Return on equity4

Financial statements

Operating income56784-$71.6M in 2022−46% since 2016
-$300.0M-$200.0M-$100.0M02016: -$133.2M-$133.2M20162017: -$182.0M-$182.0M2017+37%2018: -$220.7M-$220.7M2018+21%2019: -$128.9M-$128.9M2019−42%2020: -$72.2M-$72.2M2020−44%2021: -$32.6M-$32.6M2021−55%2022: -$71.6M-$71.6M2022+119%
Net income597842-$71.9M in 2022−46% since 2016
-$300.0M-$200.0M-$100.0M02016: -$133.1M-$133.1M20162017: -$181.0M-$181.0M2017+36%2018: -$221.6M-$221.6M2018+22%2019: -$129.1M-$129.1M2019−42%2020: -$72.6M-$72.6M2020−44%2021: -$32.4M-$32.4M2021−55%2022: -$71.9M-$71.9M2022+122%
Fiscal year20152016201720182019202020212022
Research and development$76.6M5$134.8M5$141.4M6$87.6M7$47.1M8$24.9M4$53.4M4
Operating expenses$71.6M4
Operating income-$133.2M5-$182.0M5-$220.7M6-$128.9M7-$72.2M8-$32.6M4-$71.6M4
Interest$05$1.1M5$7.5M6$7.5M7$4.4M8$799.0K4$27.0K4
Income before tax-$71.6M4
Income tax-$17.0K5-$1.1M5$921.0K6$133.0K7$438.0K8-$212.0K4$259.0K4
Net income-$133.1M5-$181.0M5-$221.6M9-$129.1M7-$72.6M8-$32.4M4-$71.9M2
Earnings per share-$0.624-$0.984
Earnings per share (diluted)-$0.624-$0.984
Shares (weighted, basic)73.2M shares4
Shares (weighted, diluted)73.2M shares4

Compare Sio Gene Therapies Inc. with another company

Corporate structure

Sio Gene Therapies Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sio Gene Therapies Inc.

  • Sio Gene Therapies Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sio Gene Therapies Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$900.0K4 Mar 31, 2022$478.0K4 Mar 31, 2021+88.3%
Operating-lease assets (leased space)$2.4M4 Mar 31, 2022$1.2M4 Mar 31, 2021+112.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$63.7M4 Mar 31, 2022$119.0M4 Mar 31, 2021−46.4%

Leadership

Who has led Sio Gene Therapies Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Pavan Cheruvu2018–2021
  2. David W. Nassif2022

Chief financial officer

  1. David W. Nassif2021–2022
20202025
Board members and other officers (36)

Former names

  • Axovant Gene Therapies Ltd.Jun 6, 2019 to Nov 13, 20203
  • Roivant Neurosciences Ltd.Mar 24, 2015 to Mar 24, 20153
  • Axovant Sciences Ltd.Jan 8, 2015 to Apr 18, 20193

Timeline

  1. Apr 6, 20238-K Executive or director change; Shareholder vote48
  2. Mar 15, 20238-K Listing notice or transfer49
  3. Feb 14, 20238-K Results of operations50
  4. Dec 14, 20228-K Other events51
  5. Nov 10, 20228-K Results of operations52
  6. Sep 14, 20228-K Listing notice or transfer53
  7. Aug 11, 20228-K Results of operations54
  8. Jun 14, 20228-K Results of operations55
  9. Apr 27, 20228-K Ended a material agreement; Results of operations; Exit or restructuring costs56
  10. Mar 18, 20228-K Listing notice or transfer57
  11. Feb 11, 20228-K Results of operations58
  12. Feb 10, 2022New chief executive David W. Nassif becomes CEO13
  13. Feb 9, 20228-K Regulation FD disclosure59
  14. Feb 15, 2018New chief executive Pavan Cheruvu becomes CEO14

Calendar

When it reported results

  1. Feb 14, 2023Reported quarterly or annual results50
  2. Nov 10, 2022Reported quarterly or annual results52
  3. Aug 11, 2022Reported quarterly or annual results54
  4. Jun 14, 2022Reported quarterly or annual results55
  5. Apr 27, 2022Reported quarterly or annual results56
  6. Feb 11, 2022Reported quarterly or annual results58
  7. Jan 31, 2022Reported quarterly or annual results60
  8. Nov 12, 2021Reported quarterly or annual results61

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

46 filings to the SEC since October 2021: 1 annual reports, 5 quarterly reports, 20 major events, 5 insider forms, 4 large holders, 11 other. The latest 20:

  1. Apr 25, 202315-12G EDGAR
  2. Apr 24, 2023EFFECT EDGAR
  3. Apr 17, 2023POS AM EDGAR
  4. Apr 17, 2023S-8 POS EDGAR
  5. Apr 6, 202325 EDGAR
  6. Apr 6, 20238-K EDGAR
  7. Mar 17, 2023DEFA14A EDGAR
  8. Mar 15, 20238-K EDGAR
  9. Feb 21, 2023DEFM14A EDGAR
  10. Feb 14, 2023DEFA14A EDGAR
  11. Feb 14, 20238-K EDGAR
  12. Feb 14, 202310-Q EDGAR
  13. Feb 13, 2023SC 13G/A EDGAR
  14. Feb 10, 2023SC 13G EDGAR
  15. Feb 9, 2023PREM14A EDGAR
  16. Dec 14, 2022DEFA14A EDGAR
  17. Dec 14, 20228-K EDGAR
  18. Nov 10, 20228-K EDGAR
  19. Nov 10, 202210-Q EDGAR
  20. Sep 14, 20228-K EDGAR

The 46 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Sio Gene Therapies Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSio Gene Therapies Inc.1
  • CIK0001636050
  • Employer ID (EIN)85-38633151
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address1501 Broadway, 12Th Floor, New York, NY 100361
  • Phone877-746-48911
  • Shares outstanding73,975,196 as of Feb 10, 20232
  • Public float$117.4M as of Sep 30, 20214
  • On EDGAR sinceMar 24, 20151
  • Filings466 in all: 4 (128), 8-K (105), 3 (45), SC 13D/A (34), 10-Q (24), 424B5 (12), SC 13G/A (11), SC 13G (9)1
    All 44 form types

    10-K (7), DEF 14A (7), EFFECT (7), SC 13D (7), CORRESP (6), S-8 (6), CT ORDER (5), DEFA14A (5), UPLOAD (5), 8-K/A (4), DEF 14C (4), PRE 14C (4), POS AM (3), 25 (2), 8-A12B (2), S-1/A (2), S-3 (2), S-8 POS (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-K12G3 (1), CERTNAS (1), CERTNYS (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), PRE 14A (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3/A (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Jun 14, 2022
    Quarterly report (10-Q) Feb 14, 2023
    Proxy statement (DEF 14A) Aug 6, 2021
    Latest 8-K (8-K) Apr 6, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64